yingweiwo
  1. Home
  2. Products
  3. Signaling Pathways
  4. Anti-infection
  5. SARS-CoV

SARS-CoV

SARS-CoV

The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.

The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.

SARS-CoV related products

Structure Cat No. Product Name CAS No. Product Description
SARS-CoV-2 Mpro-IN-22 V90918 SARS-CoV-2 Mpro-IN-22 1236310-35-2 SARS-CoV-2 Mpro-IN-22 (compound 4) is a hydrolyzable tannin and a potent SARS-CoV-2 major protease (Mpro) inhibitor with an IC50 value of 1.2 µg/mL.
SARS-CoV-2 Mpro-IN-25 V97175 SARS-CoV-2 Mpro-IN-25 2205006-23-9 SARS-CoV-2 Mpro-IN-25 (compound 3a) is a SARS-CoV-2 protease inhibitor with IC50 value of 0.26 μM.
SARS-CoV-2 Mpro-IN-26 V94902 SARS-CoV-2 Mpro-IN-26 SARS-CoV-2 Mpro-IN-26 (compound 13) is a covalent inhibitor of SARS-CoV-2 Mpro.
SARS-CoV-2 Mpro-IN-27 V94047 SARS-CoV-2 Mpro-IN-27 SARS-CoV-2 Mpro-IN-27 (compound 4h) is a potent SARS-CoV-2 Mpro inhibitor.
SARS-CoV-2 Mpro-IN-28 V93709 SARS-CoV-2 Mpro-IN-28 2443360-60-7 SARS-CoV-2 Mpro-IN-28 (Compound 1K) is a SARS-CoV-2 Mpro inhibitor with EC50 of 24 μM.
SARS-CoV-2 Mpro-IN-29 V103682 SARS-CoV-2 Mpro-IN-29 SARS-CoV-2 Mpro-IN-29 (compound 7) is an inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 310 nM for Mpro and an EC50 of 0.5 μM in Vero cells.
SARS-CoV-2 Mpro-IN-3 V78148 SARS-CoV-2 Mpro-IN-3 3031351-76-2 SARS-CoV-2 Mpro-IN-3 is a potent Mpro inhibitor (antagonist) with IC50 of >5 μM.
SARS-CoV-2 Mpro-IN-31 V93260 SARS-CoV-2 Mpro-IN-31 870153-73-4 SARS-CoV-2 Mpro-IN-31 (Compound 18) is a SARS-CoV-2 MPro inhibitor with IC50 of 11 nM.
SARS-CoV-2 Mpro-IN-32 V93243 SARS-CoV-2 Mpro-IN-32 2961016-95-3 SARS-CoV-2 Mpro-IN-32 (Compound 1) is a selective SARS-CoV-2 MPro inhibitor with IC50 of 230 nM.
SARS-CoV-2 Mpro-IN-35 V105131 SARS-CoV-2 Mpro-IN-35 SARS-CoV-2 Mpro-IN-35 (Compound 14) is an inhibitor of SARS-CoV-2 Mpro.
SARS-CoV-2 Mpro-IN-4 V78350 SARS-CoV-2 Mpro-IN-4 SARS-CoV-2 Mpro-IN-4 is a dual (bifunctional) inhibitor of major protease (MPro) and cathepsin L (CatL) with IC50s of 900 nM and 60 nM respectively.
SARS-CoV-2 Mpro-IN-5 V81362 SARS-CoV-2 Mpro-IN-5 SARS-CoV-2 Mpro-IN-5 is a dual (bifunctional) inhibitor of major protease (MPro) and cathepsin L (CatL) with IC50s of 1800 nM and 145 nM respectively.
SARS-CoV-2 Mpro-IN-6 V37550 SARS-CoV-2 Mpro-IN-6 2768834-48-4 SARS-CoV-2 Mpro-IN-6 is a covalent, irreversible and selective inhibitor of SARS-CoV-2 Mpro with IC50 of 0.18 μM.
SARS-CoV-2 Mpro-IN-7 V81363 SARS-CoV-2 Mpro-IN-7 Mpro-IN-7 (compound 6g) is a potent inhibitor of Mpro-SARS-CoV-2 (IC50=8.8 μM, CC50=10 μM).
SARS-CoV-2 Mpro-IN-8 V77958 SARS-CoV-2 Mpro-IN-8 SARS-CoV-2 Mpro-IN-8 (compound 6b) is an antiviral drug with anti-SARS-CoV-2 properties.
SARS-CoV-2 Mpro-IN-9 V54400 SARS-CoV-2 Mpro-IN-9 2754370-99-3 SARS-CoV-2 Mpro-IN-9 (compound c7) is a non-peptide, non-covalent SARS-CoV-2 Mpro inhibitor (IC50=0.085 μM) with improved physicochemical, drug metabolism and pharmacokinetics Learn (DMPK) properties.
SARS-CoV-2 nsp14-IN-1 V75483 SARS-CoV-2 nsp14-IN-1 2816165-02-1 SARS-CoV-2 nsp14-IN-1 (Compound 3) is a typical dual-substrate inhibitor of SARS-CoV-2 Nsp14 MTase, with an activity IC50 of 0.061 μM.
SARS-CoV-2 nsp14-IN-2 V76077 SARS-CoV-2 nsp14-IN-2 2816165-16-7 SARS-CoV-2 nsp14-IN-2 is a potent inhibitor of SARS-CoV-2 Nsp14 methyltransferase with IC50 of 0.093 µM.
SARS-CoV-2 nsp14-IN-3 V54372 SARS-CoV-2 nsp14-IN-3 2920574-16-7 SARS-CoV-2 nsp14-IN-3 (4975) is an inhibitor (blocker/antagonist) of SARS-CoV-2 Nsp14 N7-methyltransferase (IC50= 7 μM).
SARS-CoV-2 nsp14-IN-4 V81364 SARS-CoV-2 nsp14-IN-4 SARS-CoV-2 nsp14-IN-4 (Compound 12q) is an inhibitor (blocker/antagonist) of SARS-CoV-2 nsp14 methyltransferase (IC50 is 19 nM).
Contact Us
Tel: 1-708-310-1919 Fax: 1-708-557-7486 Email: sales@invivochem.com Frequently Asked Questions
Subscribe to our E-newsletter
Name
E-mail

Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved

linkedin facebook
Contact Us
Home Product Cart Member